Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Abstract Text:

Reiki Nishimura,Yasuhiro Okumura,Nobuyuki Arima,

BACKGROUND: HER2 expression is an important prognostic and predictive factor of treatment efficacy in breast cancer. Trastuzumab, in particular, is a key drug in the treatment of HER2-positive recurrent breast cancer. However, the difference in treatment efficacy between trastuzumab monotherapy and combination therapy with chemotherapy is unclear. In order to elucidate this point, both treatments were compared in terms of efficacy by metastatic site, time to progression (TTP), and survival. PATIENTS AND METHODS: The subjects were 1,471 breast cancer patients who had been evaluated for HER2 expression between 1998 and March 2006; 74 of these had recurrent breast cancer that had been treated with trastuzumab. Of these 74 patients, 39 received trastuzumab alone and 45 trastuzumab in combination with chemotherapy. The items of investigation were clinical effect, TTP, survival, biological markers such as ER/PgR, proliferation (Ki67) or p53 overexpression, nuclear grade, performance status (PS), lymph node metastasis, and tumor size. RESULTS: The HER2-positive rate was 23.3%, and the degree of malignancy in these HER2-positive patients was high; postoperative disease-free survival (DFS) was low. However, this tendency was clear in patients with hormone-responsive breast cancer. In patients with hormone-non-responsive breast cancer, HER2 negativity had a significantly higher Ki67 value, and there was no difference in DFS between patients with HER2-positive and -negative tumors. Among the 74 patients with recurrent breast cancer, the response rate to trastuzumab was 64.9%; however, among patients who received the combination treatment, the response rate was 86%. In patients with liver metastasis, the effect of trastuzumab alone was low, but that of the combination treatment was significantly high. TTP was 5.7 months and 15.9 months with trastuzumab alone and the combination therapy, respectively. Furthermore, a significant difference was seen in post-treatment survival; however, there was no significant difference in survival after a recurrence. In the multivariate analysis on factors for TTP, PS, clinical effect, and combination treatment were significant. However, good PS and early treatment were the significant factors in post-treatment survival. CONCLUSIONS: The effect of trastuzumab in patients with recurrent breast cancer who received the combination treatment was significantly high and TTP was long. However, this was not a significant factor in terms of overall survival. In particular, a good PS and early treatment were important in post-treatment survival.

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Publishing Authors By Initials

R Nishimura,Y Okumura,N Arima,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Breast cancer (Tokyo, Japan)

VOLUME: 15

Page Numbers: 57-64

Journal Abbreviation: Breast Cancer

ISSN: 1880-4233

DAY: 28

MONTH: 01

YEAR: 2008

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100888201

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.

AFFILIATION: Department of Breast & Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, Kumamoto, Kumamoto, 862-8505, Japan, j_nishimura2002@yahoo.co.jp.

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Breast Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival Related Publications

• Aberrant DNA methylation of imprinted loci in sperm from oligospermic patients.
• Aggressive NK cell leukaemia after splenectomy: association with CD95-resistant memory T-cell proliferation and recalcitrant clinical course of haemophagocytic syndrome.
• Clinical manifestations of human T lymphotropic virus type I-infected patients with systemic lupus erythematosus.
• Correlated oxides: Sliding electrons take charge.
• Environment of tryptophan residues in alpha-lactalbumin.
• Evidence for the role of disulfide bonds in the masking of chromophore groups in bovine kappa-casein.
• Extensive loss of arterial medial smooth muscle cells and mural extracellular matrix in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL).
• Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells.
• Kinetic studies on the ES-complex formation of p-hydroxybenzoate hydroxylase using the stopped-flow method.
• L-Alloisocitrate dehydrogenase and oxalosuccinate decarboxylase from a Pseudomonas sp. utilizing L-alloisocitrate.
• Magnetic Control of Crystal Chirality and the Existence of a Large Magneto-Optical Dichroism Effect in CuB2O4.
• Polarization Reversal in Multiferroic TbMnO3 with a Rotating Magnetic Field Direction.
• Potential use of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA.
• Properties of the colicin E 2 -induced degradation of deoxyribonucleic acid in Escherichia coli.
• Pseudorotaxane-Like Supramolecular Complex of Coenzyme Q10 with gamma-Cyclodextrin Formed by Solubility Method.
• Purification of prorennin and production of its antibody.
• Recent progress in understanding the diversity of the human ov-serpin/clade B serpin family.
• Split-root study of autoregulation of nodulation in the model legume Lotus japonicus.
• Studies on NADP-+-specific isocitrate dehydrogenase from an extreme thermophile, Thermus flavus AT-62.
• Studies on homoserine dehydrogenase from an extreme thermophile, Thermus flavus AT-62. Partial purification and properties.
• The structure and function of acid proteases. IV. Inactivation of the acid protease from Mucor pusillus by acid protease-specific inhibitors.
• Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
• Tryptic digestion of colicin E2 and its active fragment.
• [A comment on the qualification of the visiting nurse: a requirement for a minimum of 2 years in clinical experience]